Botulinum Toxin and the Bladder: Future Research Directions
Author:
Apostolidis Apostolos
Publisher
Springer Netherlands
Reference28 articles.
1. Mangera A, Andersson KE, Apostolidis A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011;60:784–95.
2. Tyagi P, Kashyap M, Yoshimura N, et al. Past, present and future of chemodenervation with botulinum toxin in the treatment of overactive bladder. J Urol. 2017;197:982–90.
3. Krhut J, Zvara P. Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial. Int Urol Nephrol. 2011;43:337–43.
4. Chuang YC, Yoshimura N, Huang CC, et al. Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur Urol. 2009;56:159–66.
5. Kajbafzadeh AM, Ahmadi H, Montaser-Kouhsari L, et al. Intravesical electromotive botulinum toxin type A administration-part II: clinical application. Urology. 2011;77:439–45.